Claritev (CTEV) AI Stock Analysis

• Market Cap: $1.20B
• Dividend Yield: N/A
• Average Volume (3M): 123.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: -2.03%
• EPS Growth: 43.59%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -3.81
• Shares Outstanding: 16,474,834
• 10 Day Avg. Volume: 118,118
• 30 Day Avg. Volume: 123,013
• PEG Ratio: >-0.01
• Price to Book (P/B): 5.61
• Price to Sales (P/S): 0.51
• P/FCF Ratio: -44.88
• Enterprise Value/Market Cap: 4.45
• Enterprise Value/Revenue: 5.69
• Enterprise Value/Gross Profit: 9.10
• Enterprise Value/Ebitda: 280.82
• 1Y Price Target: $68.00
• Price Target Upside: -6.31% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 54 Neutral
• Price Target: $56.00 ▼(-22.84% Downside)

Claritev's stock score is primarily impacted by its poor financial performance, characterized by significant losses and high leverage. While technical analysis indicates strong momentum, overbought conditions could lead to a pullback. The negative P/E ratio and lack of dividend yield further weigh on the overall score.

Claritev Business Overview & Revenue Model

Company Description

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.

How the Company Makes Money

Claritev generates revenue primarily through a subscription-based model for its software applications, offering tiered pricing plans based on the features and services utilized by its clients. Additionally, the company earns income through implementation services, where it assists businesses in integrating its solutions into their existing systems. Claritev also engages in strategic partnerships with telecommunications providers and technology firms to expand its market reach, which contributes to its revenue through joint ventures and co-branded product offerings. Furthermore, the company may earn revenue from consultancy services, providing expert advice and tailored solutions to enhance operational efficiency for its clients.

Claritev Financial Statement Overview

Summary

Claritev's financial performance is severely challenged, with declining revenues, negative profitability, and high leverage. The income statement indicates significant losses, and the balance sheet reveals heavy reliance on debt. Although there is some positive cash flow from operations, the overall financial health is concerning.

Income Statement

Claritev's income statement reveals significant challenges, with declining revenue and persistent losses. The TTM data shows a gross profit margin of 74.15%, but the net profit margin is deeply negative at -126.96%, indicating substantial losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. The revenue growth rate has been negative, highlighting a downward trajectory in sales.

Balance Sheet

The balance sheet indicates a precarious financial position with a high debt-to-equity ratio of 312.35, suggesting heavy reliance on debt financing. The equity ratio is a mere 0.29%, pointing to minimal equity backing. Return on equity is negative due to consistent losses, raising concerns about shareholder value.

Cash Flow

Cash flow analysis shows some resilience with positive operating cash flow, but free cash flow remains negative, indicating cash outflows from capital expenditures. The operating cash flow to net income ratio is positive, suggesting some ability to generate cash despite losses. However, free cash flow growth is negative, reflecting ongoing cash challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	935.54M	930.62M	961.52M	1.08B	1.12B	937.76M
Gross Profit	585.09M	691.22M	726.06M	875.62M	942.31M	619.09M
EBITDA	18.96M	-1.01B	651.93M	158.32M	814.99M	192.41M
Net Income	-663.37M	-1.65B	-91.70M	-572.91M	102.08M	-520.56M
Balance Sheet
Total Assets	5.07B	5.15B	6.96B	7.37B	8.22B	8.28B
Cash, Cash Equivalents and Short-Term Investments	56.39M	16.85M	71.55M	334.05M	185.33M	126.75M
Total Debt	4.57B	4.54B	4.57B	4.78B	4.93B	4.61B
Total Liabilities	5.11B	5.07B	5.26B	5.58B	5.88B	5.73B
Stockholders Equity	-39.91M	84.02M	1.71B	1.79B	2.34B	2.56B
Cash Flow
Free Cash Flow	-55.01M	-10.51M	62.87M	282.63M	320.10M	306.56M
Operating Cash Flow	70.61M	107.62M	171.72M	372.36M	404.69M	377.37M
Investing Cash Flow	-125.62M	-118.12M	-249.79M	-104.45M	-228.38M	-210.84M
Financing Cash Flow	63.13M	-41.31M	-180.99M	-115.74M	-114.68M	-61.60M

Claritev Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 72.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Positive. The current price of 72.58 is above the 20-day moving average (MA) of 59.34, above the 50-day MA of 49.74, and above the 200-day MA of 26.79, indicating a bullish trend. The MACD of 7.49 indicates Negative momentum. The RSI at 72.42 is Negative, neither overbought nor oversold. The STOCH value of 93.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTEV.

Claritev Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	75 Outperform	$829.95M	41.71	5.81%	0.44%	3.50%	13.99%
NUTX	67 Neutral	$500.24M	7.56	51.65%	―	141.25%	―
EVH	55 Neutral	$1.09B	―	-13.38%	―	-6.71%	-71.40%
CTEV	54 Neutral	$1.20B	―	-235.47%	―	-2.03%	43.59%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
DH	49 Neutral	$568.50M	―	-64.27%	―	-5.24%	23.59%
HCAT	46 Neutral	$246.31M	―	-28.42%	―	5.55%	-0.99%

Claritev Corporate Events

Claritev Shareholders Approve Omnibus Incentive Plan Amendment

On April 30, 2025, Claritev Corporation’s stockholders approved an amendment to the 2020 Omnibus Incentive Plan, increasing the shares reserved for issuance by 1,750,000. At the same annual meeting, stockholders elected three Class II directors, ratified PricewaterhouseCoopers LLP as the independent auditor for 2025, and approved executive compensation, indicating strong shareholder support for the company’s governance and strategic decisions.